Ropivacaine
In clinical developmentAlso known as (S)-(-)-1-propyl-2',6'-pipecoloxylidide, (S)-ropivacaine, Naropin, Ropivacaina+4 more
(S)-(-)-1-propyl-2',6'-pipecoloxylidide, (S)-ropivacaine, Naropin, Ropivacaina, ropivicaine, L-N-n-propylpipecolic acid-2,6-xylidide, Ropivacaine Hydrochloride, Ropivacainum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Post-operative Pain Control With Sphenopalantine Ganglion Nerve Block in Septorhinoplasty Patients
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Pre-Operative and Post-Operative Paravertebral Block on Patients With Thoracic Outlet Syndrome.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- JAMA psychiatry1
- Journal of clinical medicine1
- Bartoszek M1
- Constantinescu O1
- Croxford J1
- Díaz-Álvarez A1
- González-Rodríguez JL1
- Hirsch S1
- Kane S1
- Kim E1
- Instituto de Investigación Biomédica de Salamanca de la FIESCYL (IBSAL-FIESCYL)1
- John F. Kennedy Special Warfare Center and School1
- Landstuhl Regional Medical Center1
- Salamanca University1
- Salamanca University Hospital1
- Tripler Army Medical Center1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials